Stevanato has been investing hundreds of millions in new plants to meet biologic and GLP-1 demand, suppressing free cash flow. This heavy capex cycle is now ending. As spending normalizes, the company is set to become highly free cash flow positive, combining margin expansion and revenue growth with significant cash generation.

Judging an early-stage company on its current gross margins is a mistake. The key indicator of future profitability is its potential pricing power. A defensible, sticky product that can consistently raise prices over time is a much stronger signal than one that relies solely on falling costs.

When a pharmaceutical company gets a new drug approved, the specific containment system (e.g., Stevanato's vial) is part of the FDA filing. To switch suppliers, the pharma company must repeat a multi-year, multi-million dollar approval process. This "spec-in" dynamic creates immense customer lock-in and long-term revenue visibility.

Despite serving cost-sensitive sectors like agriculture, Novonesis maintains pharma-like profit margins. They achieve this by charging based on the demonstrable value their products create, such as measurable weight gain in livestock or increased output in biofuel plants.

The market is fixated on the GLP-1 risk, but this is only half the story. The other half of Stevanato's biologics business is growing at 15-18% annually. With 60% of pharma R&D now focused on biologics, the company's recent capacity expansion serves this broader, durable trend, providing a significant buffer.

AI models are accelerating antibody discovery, creating urgent demand for synthetic DNA. Twist Bioscience meets this need with express "clonal gene" orders, charging a 200% premium at nearly 100% gross margin. This high-margin revenue stream is a key, under-appreciated tailwind for the company's profitability.

The naive view is that lower prices are always better for customers. However, higher prices generate higher margins, which can be reinvested into R&D. This allows the vendor to improve the product much faster, ultimately delivering more value and making the customer better off than with a cheaper, stagnant product.

The follow-up reveals the single biggest impact came from optimizing for high-margin custom orders, which grew from 30% to 50% of the business. This validates the strategy of doubling down on your most defensible, profitable, and specialized offering rather than competing on commodity products.

Serial acquirer Brad Jacobs boils down his complex business strategy to two core objectives: growing organic revenue faster than the market and continuously expanding profit margins. Every decision is evaluated against its ability to move one of these two levers, providing a clear and powerful framework for creating shareholder value.